A $1.3bn deal between Biogen, Inc. and Capsigen Inc. points to how a growing number of large biopharma companies are turning to small firms focused on developing novel capsid technology to aid their gene therapy development efforts. Along with that, there is growing interest in adeno-associated viral (AAV) vector-based gene therapies more specifically tailored to diseases than the ones currently on the market, and the firms’ ability to net potentially billion-dollar-plus deals shows there is room for better capsids.
Biogen/Capsigen Ink Up To $1.3bn Deal For Improved AAV Capsids
Collaboration Is Latest Focused On Next-Generation Gene Therapies
Biogen is Capsigen’s first partner, while Dyno Therapeutics has also entered into deals potentially worth billions with large drug and biotech firms.
More from Gene Therapies
• By
The company closed a $150m series C funding round shortly after opening the second part of its Phase I/II study of ATSN-201 and partnering with a Nippon Shinyaku on ATSN-101.
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
• By
The founder and CEO of Ultragenyx talked with Scrip as the company approaches a pivotal data readout and awaits US FDA action on its first gene therapy.
• By
Encouraging results in younger children with Duchenne is keeping Regenxbio on track for a potential mid-2026 filing for its gene therapy, RGX-202.
More from Advanced Therapies
• By
The founder and CEO of Ultragenyx talked with Scrip as the company approaches a pivotal data readout and awaits US FDA action on its first gene therapy.
• By
Encouraging results in younger children with Duchenne is keeping Regenxbio on track for a potential mid-2026 filing for its gene therapy, RGX-202.
• By
Miltenyi’s leadership calls for a streamlined regulatory framework as India gears to scale in cell and gene therapy. Executives from the German group also talked to Scrip about helping advance local capabilities, delivering point-of-care CAR- T cell therapy to hospitals and pricing dynamics.